Pharmaceutical

Request for TOC Request for Sample
BUY NOW

Europe Nasal Spray Market – Industry Trends and Forecast to 2030

Pharmaceutical | Published Report | Apr 2023 | Europe | 350 Pages | No of Tables: 110 | No of Figures: 49

Report Description

Europe Nasal Spray Market, By Product Type (Decongestion Nasal Spray, Steroid Nasal Spray, Salt Water Solution/Saline Nasal Spray, and Others), Container Design (Pump Bottles and Pressurized Canisters), Dosage Form (Multi Dose, Unit/Single Dose, and Bi Dose), Therapeutic Class (Antihistamine, Nasal Steroid, Mast Cell Inhibitor, and Anticholinergic), Application (Nasal Congestion, Allergic and Non-Allergic Rhinitis, Central Nervous System Disorders, Vaccination, and Others), Prescription/Availability (Over The Counter and Prescribed), End User (Home Care Settings, Hospitals, Clinics, and Community Health Care)- Industry Trends and Forecast to 2030.


Europe Nasal Spray Market Analysis and Insights

Allergic rhinitis is a major health problem that causes problems in more than 500 million people in the world. It has symptoms such as nasal congestion, snoring, postnasal drip, and cough, reduction in the sense of smell, headache, and others for months or years in almost half of the patients on earth. These symptoms can also affect the quality of life of patients.


Get Exclusive Sample Copy of this Report Here

A nasal spray is a device widely used as a system in nasal drug delivery to treat major allergy problems such as nasal congestion, infections, itchy or watery eyes, runny nose, chest congestion, cough, wheezing, labored breathing, shallow breathing, and others. Some other diseases which also include nasal polyps, inflammatory bowel disease, kidney-related problems, and others. Administration of medicines or drugs by the nose in dosage form with the help of spray is a non-invasive technique that provides rapid action of a drug in the body of patients. A nasal spray is one of the most cost-effective, does not require invasion, is easy to use and self-administered, and has high patient compliance. Therefore nasal drug delivery is one of the popular routes of drug administration in recent times and has a strong growth opportunity.

Nasal sprays are available in the market as over-the-counter (OTC) or prescription drugs for the treatment of nasal diseases such as nasal allergies, blocked or stuffy nose, chronic sinus, allergic rhinitis, and other problems associated with the nose. These sprays are available in the market as a pump or as canisters.

Data Bridge Market Research analyzes that the Europe nasal spray market is expected to reach a value of USD 9,855.26 million by 2030, at a CAGR of 6.5% during the forecast period.

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Year

2021 (Customizable to 2015-2020)

Quantitative Units

Revenue in Million, Volumes in Units, and Pricing in USD

Segments Covered

Product Type (Decongestion Nasal Spray, Steroid Nasal Spray, Salt Water Solution/Saline Nasal Spray, and Others), Container Design (Pump Bottles and Pressurized Canisters), Dosage Form (Multi Dose, Unit/Single Dose, and Bi Dose), Therapeutic Class (Antihistamine, Nasal Steroid, Mast Cell Inhibitor, and Anticholinergic), Application (Nasal Congestion, Allergic and Non-Allergic Rhinitis, Central Nervous System Disorders, Vaccination, and Others), Prescription/Availability (Over The Counter and Prescribed), End User (Home Care Settings, Hospitals, Clinics, and Community Health Care)

Countries Covered

Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey, and Rest of Europe

Market Players Covered

EMERGENT, Cipla Inc., Sandoz International GmbH (A Part of Novartis), Aytu Health (A subsidiary of Aytu BioPharma, Inc.), Bayer AG, GlaxoSmithKline plc., Assertio Therapeutics, Inc., Aurena Laboratories., J Pharmaceuticals, St. Renatus., Ultratech India Limited, Catalent, Inc., Teva Pharmaceuticals USA, Inc. (A subsidiary of Teva Pharmaceutical Industries Ltd), Pfizer Inc., Viatris Inc., LEEFORD HEALTHCARE LTD, and Aishwarya Group among others

Market Definition

Nasal sprays are devices that help in the delivery of the drug through the nose in the nasal cavity to treat allergies and other problems related to brain inflammation, diabetes, dental problems, and the central nervous system. Allergy is a condition in which the immune system of the body reacts abnormally to a foreign substance. Nasal spray drug products consist of therapeutically active ingredients or drug substances in the form of solution or suspension of excipients.

There are different types of nasal spray available in the market, such as decongestion nasal spray, saline nasal spray, and steroid nasal spray. Decongestants are devices with drugs for the treatment of nasal congestion and provide short-term relief from a blocked nose. The decongestion nasal spray consists of drugs that open up the airways of the nasal part and helps in the breathing process.

During the cold and dry winter season, saline nasal sprays are used to avoid problems related to a stuffy nose. These devices are used to treat sinusitis, nasal crusting, and thin secretions of liquid from the nose, which are formed due to bacterial infection and lead to the dryness of the nasal area. This device helps in cleaning the nasal passage and mucus present in that area due to cold.

Europe Nasal Spray Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:

DRIVER

  • Increase in Infection and Allergic Cases

Allergy is a condition that makes the immune system weaken, and the immune system reacts abnormally to a foreign substance. Allergies have many forms, such as Allergic Rhinitis (AR), and this affects nearly 40 to 50 million people in the U.S. Some allergies may interfere with day-to-day activities and the quality of life.

Due to the increase in population, urbanization, and industrialization has increased tremendously, which has led to a rise in allergen. This allergen is responsible for allergies or infectious diseases in many people.

Thus, the rise in the prevalence of allergic diseases such as AR has led to an increase in the demand for nasal sprays, which is expected to drive market growth in the coming years.

RESTRAINT

  • Adverse Effects of Using Nasal Sprays

Many people opt for nasal sprays in order to get relief from a runny and stuffy nose, but using a nasal spray for a longer period of time causes several side effects. Steroid nasal sprays, also called corticosteroid nasal sprays, are anti-inflammatory medicines that are sprayed into the nose. They can be used to treat a range of conditions, including hay fever, sinusitis, non-allergic rhinitis, and nasal polyps. Some steroid nasal sprays are available to buy from pharmacies and shops, while others are only available on prescription.

Using nasal sprays for a prolonged period of time can lead to bleeding from the nose and even headaches. Some may experience other side effects, such as addiction or even congestion.

If one is taking a high dose for a long time, there is also a small chance one could get some of the side effects of steroid tablets, such as increased appetite, mood changes, and difficulty sleeping.

Thus, the adverse effects of nasal sprays are expected to restrain the market growth.

OPPORTUNITY

  • Expanding Therapeutic Applications for Nasal Sprays

Intranasal administration provides various useful options for the local and systemic delivery of diverse therapeutic agents for the treatment of problems such as allergies, respiratory diseases, and many others.

A nasal spray is one of the recently developed products, such as OptiNose and ViaNase, that helps to enable the targeting of formulations to a specific area of the site in the nasal cavity in humans.

Nasal therapy has been known as a form of treatment in Indian medicine for decades. It is also called “NASAYA KARMA” in Ayurvedic systems in Indian medicine.

The nasal spray consists of one or more than one therapeutically active ingredients in the form of suspension or solution in a non-pressurized dispenser. The most common allergy is AR.

Apart from respiratory problems, there are other therapeutic areas such as orthopedic, renal, and many other areas, where the nasal spray is playing important role in treating and curing such problems. In the future, other treatments may be developed that can help in the treatment of other problems easily.

CHALLENGE

  • Regulatory Hurdles

Nasal drug delivery can be evaluated by many regulatory agencies, such as the U.S. FDA and the European Medicines Agency (EMA). These agencies provide a set of guidelines and regulations for any product before it is launched in the market. They allow performing various in vitro test methods for determining the characterization of nasal drug products and that should come in an acceptable range as given by such regulatory bodies.

Nasal spray can be designed as per the dose requirement of drug substances for patients suffering from nasal or any other issues. Some aspects of nasal sprays may be exceptional in the case of formulation, manufacturing, container closure system, stability, controls of critical steps, intermediates, and drug products. These aspects should be measured carefully while developing a program of nasal spray. Because of these changes ability of the product to treat patients may get affected.

Strict rules and regulations for the product for nasal spray manufacturing are more challenging for the manufacturer to get approval from regulatory agencies. The spray characteristics can be influenced by the design of the device, and by the handling of the device. Performing such tests to get the perfect result, that is, an acceptable range as given by the regulatory body, is more challenging in nasal spray manufacturing.

Post-COVID-19 Impact Analysis on the Europe Nasal Spray Market

COVID-19 had a significant impact on the generic drug market for inhalation and nasal spray, as one of the main symptoms associated with COVID-19 is shortness of breath. The demand for inhalation and nasal spray increased during the pandemic.

For instance,

  • According to a MedComm journal article published in 2021, nasal sprays demonstrated the ability to be an effective COVID-19 treatment and vaccine option

Spray formulations that may inactivate SARS-CoV-2 or restrict its entry into cells were thought to be beneficial in preventing viral spread to the lungs or surrounding people. Relaxed lockdowns and the resumption of healthcare practices are expected to accelerate market growth in the post-pandemic era. COVID-19 patients are still experiencing long-term side effects such as shortness of breath.

Recent Developments

  • In January 2023, Viatris Inc. (NASDAQ: VTRS), a Europe healthcare company, today announced that it has closed its acquisitions of Oyster Point Pharma and Famy Life Sciences to establish a new Viatris Eye Care Division. This acquisition would help the company in its business expansion.
  • In March 2023, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd, announced the launch of additional strengths for the generic version of Revlimid1 (lenalidomide capsules), in 2.5 mg, and 20 mg strengths, in the U.S. This product launch would help the company in its product portfolio expansion.

Europe Nasal Spray Market Scope

The Europe nasal spray market is segmented into seven notable segments on the basis of product type, container design, dosage form, therapeutic class, application, prescription/ availability, and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

PRODUCT TYPE

  • DECONGESTION NASAL SPRAY
  • STEROID NASAL SPRAY
  • SALT WATER SOLUTION/ SALINE NASAL SPRAY
  • OTHERS

On the basis of product type, the market is segmented into decongestion nasal spray, salt water solution/saline nasal spray, steroid nasal spray, and others.

CONTAINER DESIGN

  • PUMP BOTTLES
  • PRESSURIZED CANISTERS

On the basis of container design, the market is segmented into pressurized canisters and pump bottles.

DOSAGE FORM

  • MULTI DOSE
  • UNIT/SINGLE DOSE
  • BI DOSE

On the basis of dosage form, the market is segmented into unit/single dose, bi dose, and multi dose.

THERAPEUTIC CLASS

  • ANTIHISTAMINE
  • NASAL STEROIDS
  • MAST CELL INHIBITOR
  • ANTICHOLINERGIC

On the basis of therapeutic class, the market is segmented into antihistamine, nasal steroids, mast cell inhibitor, and anticholinergic.

APPLICATION

  • NASAL CONGESTION
  • ALLERGIC AND NON-ALLERGIC RHINITIS
  • CENTRAL NERVOUS SYSTEM DISORDERS
  • VACCINATION
  • OTHERS

On the basis of application, the market is segmented into nasal congestion, allergic and non-allergic rhinitis, central nervous system disorders, vaccination, and others.

PRESCRIPTION/AVAILABILITY

  • OVER THE COUNTER
  • PRESCRIBED

On the basis of prescription/availability, the market is segmented into over the counter and prescribed.

END USER

  • HOME CARE SETTINGS
  • HOSPITALS
  • CLINICS
  • COMMUNITY HEALTH CARE

On the basis of end user, the market is segmented into home care settings, hospitals, clinics, and community health care.


Europe Nasal Spray Market Regional Analysis/Insights

The Europe nasal spray market is segmented into seven notable segments on the basis of product type, container design, dosage form, therapeutic class, application, prescription/ availability, and end user.

The countries covered in this market report are Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey, and the rest of Europe.

In 2023, Germany is dominating the Europe nasal spray market due to the presence of key market players in the largest consumer market with high GDP.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Europe Nasal Spray Market Share Analysis

The Europe nasal spray market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breadth, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the market.

Some of the major market players operating in the Europe nasal spray market are EMERGENT, Cipla Inc., Sandoz International GmbH (A Part of Novartis), Aytu Health (A subsidiary of Aytu BioPharma, Inc.), Bayer AG, GlaxoSmithKline plc., Assertio Therapeutics, Inc., Aurena Laboratories., J Pharmaceuticals, St. Renatus., Ultratech India Limited, Catalent, Inc., Teva Pharmaceuticals USA, Inc. (A subsidiary of Teva Pharmaceutical Industries Ltd), Pfizer Inc., Viatris Inc., LEEFORD HEALTHCARE LTD, and Aishwarya Group among others.


SKU-

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTER’S FIVE FORCES MODEL

4.2 PESTEL ANALYSIS

5 INDUSTRY INSIGHTS: EUROPE NASAL SPRAY MARKET

5.1 INDUSTRY INSIGHTS

6 REGULATIONS: EUROPE NASAL SPRAY MARKET

6.1 REGULATORY SCENARIO IN EUROPE

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASE IN INFECTION AND ALLERGIC CASES

7.1.2 RISING PREVALENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA

7.1.3 EFFECTIVENESS OVER OTHER FORMS OF DRUG DELIVERY

7.1.4 IMPROVING PATIENT COMPLIANCE AND ACCEPTABILITY

7.2 RESTRAINTS

7.2.1 PRODUCT RECALLS

7.2.2 ADVERSE EFFECTS OF USING NASAL SPRAYS

7.3 OPPORTUNITIES

7.3.1 NEW RISING DEMAND FOR SELF-ADMINISTRATIVE DRUG DELIVERY

7.3.2 EXPANDING THERAPEUTIC APPLICATIONS FOR NASAL SPRAYS

7.3.3 STRATEGIC INITIATIVES TAKEN BY KEY MARKET PLAYERS

7.4 CHALLENGES

7.4.1 REGULATORY HURDLES

7.4.2 ADDICTION TO NASAL SPRAY

8 EUROPE NASAL SPRAY MARKET, BY PRODUCT TYPE

8.1 OVERVIEW

8.2 DECONGESTION NASAL SPRAY

8.3 STEROID NASAL SPRAY

8.4 SALT WATER SOLUTION/SALINE NASAL SPRAY

8.5 OTHERS

9 EUROPE NASAL SPRAY MARKET, BY CONTAINER DESIGN

9.1 OVERVIEW

9.2 PUMP BOTTLES

9.3 PRESSURIZED CANISTERS

10 EUROPE NASAL SPRAY MARKET, BY DOSAGE FORM

10.1 OVERVIEW

10.2 MULTI DOSE

10.3 UNIT/SINGLE DOSE

10.4 BI DOSE

11 EUROPE NASAL SPRAY MARKET, BY THERAPEUTIC CLASS

11.1 OVERVIEW

11.2 ANTIHISTAMINE

11.3 NASAL STEROIDS

11.4 MAST CELL INHIBITOR

11.5 ANTICHOLINERGIC

12 EUROPE NASAL SPRAY MARKET, BY APPLICATION

12.1 OVERVIEW

12.2 NASAL CONGESTION

12.3 ALLERGIC AND NON-ALLERGIC RHINITIS

12.4 CENTRAL NERVOUS SYSTEM DISORDERS

12.5 VACCINATION

12.6 OTHERS

13 EUROPE NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY

13.1 OVERVIEW

13.2 PRESCRIBED

13.3 OVER THE COUNTER

14 EUROPE NASAL SPRAY MARKET, BY END USER

14.1 OVERVIEW

14.2 HOME CARE SETTINGS

14.3 HOSPITALS

14.4 CLINICS

14.5 COMMUNITY HEALTH CARE

15 EUROPE NASAL SPRAY MARKET, BY REGION

15.1 EUROPE

15.1.1 GERMANY

15.1.2 U.K.

15.1.3 FRANCE

15.1.4 ITALY

15.1.5 SPAIN

15.1.6 SWITZERLAND

15.1.7 NETHERLANDS

15.1.8 BELGIUM

15.1.9 RUSSIA

15.1.10 TURKEY

15.1.11 REST OF EUROPE

16 EUROPE NASAL SPRAY MARKET, COMPANY LANDSCAPE

16.1 COMPANY SHARE ANALYSIS: EUROPE

17 SWOT ANALYSIS

18 COMPANY PROFILE

18.1 GLAXOSMITHKLINE PLC.

18.1.1 COMPANY SNAPSHOT

18.1.2 REVENUE ANALYSIS

18.1.3 COMPANY SHARE ANALYSIS

18.1.4 PRODUCT PORTFOLIO

18.1.5 RECENT DEVELOPMENTS

18.2 PFIZER INC.

18.2.1 COMPANY SNAPSHOT

18.2.2 REVENUE ANALYSIS

18.2.3 COMPANY SHARE ANALYSIS

18.2.4 PRODUCT PORTFOLIO

18.2.5 RECENT DEVELOPMENTS

18.3 EMERGENT

18.3.1 COMPANY SNAPSHOT

18.3.2 REVENUE ANALYSIS

18.3.3 COMPANY SHARE ANALYSIS

18.3.4 PRODUCT PORTFOLIO

18.3.5 RECENT DEVELOPMENT

18.4 SANDOZ INTERNATIONAL GMBH (A PART OF NOVARTIS)

18.4.1 COMPANY SNAPSHOT

18.4.2 REVENUE ANALYSIS

18.4.3 COMPANY SHARE ANALYSIS

18.4.4 PRODUCT PORTFOLIO

18.4.5 RECENT DEVELOPMENT

18.5 CATALENT, INC.

18.5.1 COMPANY SNAPSHOT

18.5.2 REVENUE ANALYSIS

18.5.3 COMPANY SHARE ANALYSIS

18.5.4 PRODUCT PORTFOLIO

18.5.5 RECENT DEVELOPMENTS

18.6 AYTU HEALTH (A SUBSIDIARY OF AYTU BIOPHARMA, INC.)

18.6.1 COMPANY SNAPSHOT

18.6.2 REVENUE ANALYSIS

18.6.3 PRODUCT PORTFOLIO

18.6.4 RECENT DEVELOPMENTS

18.7 AISHWARYA GROUP

18.7.1 COMPANY SNAPSHOT

18.7.2 PRODUCT PORTFOLIO

18.7.3 RECENT DEVELOPMENTS

18.8 ASSERTIO THERAPEUTICS, INC.

18.8.1 COMPANY SNAPSHOT

18.8.2 REVENUE ANALYSIS

18.8.3 PRODUCT PORTFOLIO

18.8.4 RECENT DEVELOPMENT

18.9 AURENA LABORATORIES.

18.9.1 COMPANY SNAPSHOT

18.9.2 PRODUCT PORTFOLIO

18.9.3 RECENT DEVELOPMENTS

18.1 BAYER AG

18.10.1 COMPANY SNAPSHOT

18.10.2 REVENUE ANALYSIS

18.10.3 COMPANY SHARE ANALYSIS

18.10.4 PRODUCT PORTFOLIO

18.10.5 RECENT DEVELOPMENTS

18.11 CIPLA INC.

18.11.1 COMPANY SNAPSHOT

18.11.2 REVENUE ANALYSIS

18.11.3 PRODUCT PORTFOLIO

18.11.4 RECENT DEVELOPMENT

18.12 J PHARMACEUTICALS.

18.12.1 COMPANY SNAPSHOT

18.12.2 PRODUCT PORTFOLIO

18.12.3 RECENT DEVELOPMENTS

18.13 LEEFORD HEALTHCARE LTD

18.13.1 COMPANY SNAPSHOT

18.13.2 PRODUCT PORTFOLIO

18.13.3 RECENT DEVELOPMENTS

18.14 ST. RENATUS.

18.14.1 COMPANY SNAPSHOT

18.14.2 PRODUCT PORTFOLIO

18.14.3 RECENT DEVELOPMENTS

18.15 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD)

18.15.1 COMPANY SNAPSHOT

18.15.2 REVENUE ANALYSIS

18.15.3 PRODUCT PORTFOLIO

18.15.4 RECENT DEVELOPMENTS

18.16 ULTRATECH INDIA LIMITED

18.16.1 COMPANY SNAPSHOT

18.16.2 PRODUCT PORTFOLIO

18.16.3 RECENT DEVELOPMENTS

18.17 VIATRIS INC.

18.17.1 COMPANY SNAPSHOT

18.17.2 REVENUE ANALYSIS

18.17.3 COMPANY SHARE ANALYSIS

18.17.4 PRODUCT PORTFOLIO

18.17.5 RECENT DEVELOPMENT

19 QUESTIONNAIRE

20 RELATED REPORTS

List of Table

TABLE 1 EUROPE NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 2 EUROPE DECONGESTION NASAL SPRAY IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 3 EUROPE STEROID NASAL SPRAY IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 4 EUROPE SALT WATER SOLUTION/SALINE NASAL SPRAY IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 5 EUROPE OTHERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 6 EUROPE NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 7 EUROPE PUMP BOTTLES IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 8 EUROPE PRESSURIZED CANISTERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 9 EUROPE NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 10 EUROPE MULTI DOSE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 11 EUROPE UNIT/SINGLE DOSE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 12 EUROPE BI DOSE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 13 EUROPE NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 14 EUROPE ANTIHISTAMINE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 15 EUROPE NASAL STEROIDS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 16 EUROPE MAST CELL INHIBITOR IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 17 EUROPE ANTICHOLINERGIC IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 18 EUROPE NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 19 EUROPE NASAL CONGESTION IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 20 EUROPE ALLERGIC AND NON-ALLERGIC RHINITIS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 21 EUROPE CENTRAL NERVOUS SYSTEM DISORDERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 22 EUROPE VACCINATION IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 23 EUROPE OTHERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 24 EUROPE NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 25 EUROPE PRESCRIBED IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 EUROPE OVER THE COUNTER IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 27 EUROPE NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 28 EUROPE HOME CARE SETTINGS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 29 EUROPE HOSPITALS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 30 EUROPE CLINICS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 31 EUROPE COMMUNITY HEALTH CARE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 32 EUROPE NASAL SPRAY MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 33 EUROPE NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 34 EUROPE NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 35 EUROPE NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 36 EUROPE NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 37 EUROPE NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 38 EUROPE NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 39 EUROPE NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 40 GERMANY NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 41 GERMANY NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 42 GERMANY NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 43 GERMANY NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 44 GERMANY NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 45 GERMANY NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 46 GERMANY NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 47 U.K. NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 48 U.K. NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 49 U.K. NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 50 U.K. NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 51 U.K. NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 52 U.K. NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 53 U.K. NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 54 FRANCE NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 55 FRANCE NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 56 FRANCE NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 57 FRANCE NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 58 FRANCE NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 59 FRANCE NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 60 FRANCE NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 61 ITALY NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 62 ITALY NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 63 ITALY NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 64 ITALY NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 65 ITALY NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 66 ITALY NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 67 ITALY NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 68 SPAIN NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 69 SPAIN NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 70 SPAIN NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 71 SPAIN NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 72 SPAIN NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 73 SPAIN NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 74 SPAIN NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 75 SWITZERLAND NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 76 SWITZERLAND NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 77 SWITZERLAND NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 78 SWITZERLAND NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 79 SWITZERLAND NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 80 SWITZERLAND NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 81 SWITZERLAND NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 82 NETHERLANDS NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 83 NETHERLANDS NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 84 NETHERLANDS NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 85 NETHERLANDS NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 86 NETHERLANDS NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 87 NETHERLANDS NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 88 NETHERLANDS NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 89 BELGIUM NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 90 BELGIUM NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 91 BELGIUM NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 92 BELGIUM NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 93 BELGIUM NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 94 BELGIUM NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 95 BELGIUM NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 96 RUSSIA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 97 RUSSIA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 98 RUSSIA NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 99 RUSSIA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 100 RUSSIA NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 101 RUSSIA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 102 RUSSIA NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 103 TURKEY NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 104 TURKEY NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 105 TURKEY NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 106 TURKEY NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 107 TURKEY NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 108 TURKEY NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 109 TURKEY NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 110 REST OF EUROPE NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

List of Figure

FIGURE 1 EUROPE NASAL SPRAY MARKET: SEGMENTATION

FIGURE 2 EUROPE NASAL SPRAY MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE NASAL SPRAY MARKET: DROC ANALYSIS

FIGURE 4 EUROPE NASAL SPRAY MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE NASAL SPRAY MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE NASAL SPRAY MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE NASAL SPRAY MARKET: DBMR MARKET POSITION GRID

FIGURE 8 EUROPE NASAL SPRAY MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 EUROPE NASAL SPRAY MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE NASAL SPRAY MARKET: SEGMENTATION

FIGURE 11 THE INCREASE IN INFECTION AND ALLERGIC CASES IS EXPECTED TO DRIVE THE EUROPE NASAL SPRAY MARKET IN THE FORECAST PERIOD

FIGURE 12 THE DECONGESTION NASAL SPRAY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE NASAL SPRAY MARKET IN 2023 AND 2030

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE EUROPE NASAL SPRAY MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD

FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR EUROPE NASAL SPRAY MARKET MANUFACTURERS IN THE FORECAST PERIOD

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE NASAL SPRAY MARKET

FIGURE 16 EUROPE NASAL SPRAY MARKET: BY PRODUCT TYPE, 2022

FIGURE 17 EUROPE NASAL SPRAY MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)

FIGURE 18 EUROPE NASAL SPRAY MARKET: BY PRODUCT TYPE, CAGR (2023-2030)

FIGURE 19 EUROPE NASAL SPRAY MARKET: BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 20 EUROPE NASAL SPRAY MARKET: BY CONTAINER DESIGN, 2022

FIGURE 21 EUROPE NASAL SPRAY MARKET: BY CONTAINER DESIGN, 2023-2030 (USD MILLION)

FIGURE 22 EUROPE NASAL SPRAY MARKET: BY CONTAINER DESIGN, CAGR (2023-2030)

FIGURE 23 EUROPE NASAL SPRAY MARKET: BY CONTAINER DESIGN, LIFELINE CURVE

FIGURE 24 EUROPE NASAL SPRAY MARKET: BY DOSAGE FORM, 2022

FIGURE 25 EUROPE NASAL SPRAY MARKET: BY DOSAGE FORM, 2023-2030 (USD MILLION)

FIGURE 26 EUROPE NASAL SPRAY MARKET: BY DOSAGE FORM, CAGR (2023-2030)

FIGURE 27 EUROPE NASAL SPRAY MARKET: BY DOSAGE FORM, LIFELINE CURVE

FIGURE 28 EUROPE NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, 2022

FIGURE 29 EUROPE NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, 2023-2030 (USD MILLION)

FIGURE 30 EUROPE NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, CAGR (2023-2030)

FIGURE 31 EUROPE NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, LIFELINE CURVE

FIGURE 32 EUROPE NASAL SPRAY MARKET: BY APPLICATION, 2022

FIGURE 33 EUROPE NASAL SPRAY MARKET: BY APPLICATION, 2023-2030 (USD MILLION)

FIGURE 34 EUROPE NASAL SPRAY MARKET: BY APPLICATION, CAGR (2023-2030)

FIGURE 35 EUROPE NASAL SPRAY MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 36 EUROPE NASAL SPRAY MARKET: BY PRESCRIPTION/AVAILABILITY, 2022

FIGURE 37 EUROPE NASAL SPRAY MARKET: BY PRESCRIPTION/AVAILABILITY, 2023-2030 (USD MILLION)

FIGURE 38 EUROPE NASAL SPRAY MARKET: BY PRESCRIPTION/AVAILABILITY, CAGR (2023-2030)

FIGURE 39 EUROPE NASAL SPRAY MARKET: BY PRESCRIPTION/AVAILABILITY, LIFELINE CURVE

FIGURE 40 EUROPE NASAL SPRAY MARKET: BY END USER, 2022

FIGURE 41 EUROPE NASAL SPRAY MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 42 EUROPE NASAL SPRAY MARKET: BY END USER, CAGR (2023-2030)

FIGURE 43 EUROPE NASAL SPRAY MARKET: BY END USER, LIFELINE CURVE

FIGURE 44 EUROPE NASAL SPRAY MARKET: SNAPSHOT (2022)

FIGURE 45 EUROPE NASAL SPRAY MARKET: BY COUNTRY (2022)

FIGURE 46 EUROPE NASAL SPRAY MARKET: BY COUNTRY (2023 & 2030)

FIGURE 47 EUROPE NASAL SPRAY MARKET: BY COUNTRY (2022 & 2030)

FIGURE 48 EUROPE NASAL SPRAY MARKET: PRODUCT TYPE (2023-2030)

FIGURE 49 EUROPE NASAL SPRAY MARKET: COMPANY SHARE 2022 (%)

View Infographics

FIGURE 1 EUROPE NASAL SPRAY MARKET: SEGMENTATION

FIGURE 2 EUROPE NASAL SPRAY MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE NASAL SPRAY MARKET: DROC ANALYSIS

FIGURE 4 EUROPE NASAL SPRAY MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE NASAL SPRAY MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE NASAL SPRAY MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE NASAL SPRAY MARKET: DBMR MARKET POSITION GRID

FIGURE 8 EUROPE NASAL SPRAY MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 EUROPE NASAL SPRAY MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE NASAL SPRAY MARKET: SEGMENTATION

FIGURE 11 THE INCREASE IN INFECTION AND ALLERGIC CASES IS EXPECTED TO DRIVE THE EUROPE NASAL SPRAY MARKET IN THE FORECAST PERIOD

FIGURE 12 THE DECONGESTION NASAL SPRAY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE NASAL SPRAY MARKET IN 2023 AND 2030

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE EUROPE NASAL SPRAY MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD

FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR EUROPE NASAL SPRAY MARKET MANUFACTURERS IN THE FORECAST PERIOD

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE NASAL SPRAY MARKET

FIGURE 16 EUROPE NASAL SPRAY MARKET: BY PRODUCT TYPE, 2022

FIGURE 17 EUROPE NASAL SPRAY MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)

FIGURE 18 EUROPE NASAL SPRAY MARKET: BY PRODUCT TYPE, CAGR (2023-2030)

FIGURE 19 EUROPE NASAL SPRAY MARKET: BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 20 EUROPE NASAL SPRAY MARKET: BY CONTAINER DESIGN, 2022

FIGURE 21 EUROPE NASAL SPRAY MARKET: BY CONTAINER DESIGN, 2023-2030 (USD MILLION)

FIGURE 22 EUROPE NASAL SPRAY MARKET: BY CONTAINER DESIGN, CAGR (2023-2030)

FIGURE 23 EUROPE NASAL SPRAY MARKET: BY CONTAINER DESIGN, LIFELINE CURVE

FIGURE 24 EUROPE NASAL SPRAY MARKET: BY DOSAGE FORM, 2022

FIGURE 25 EUROPE NASAL SPRAY MARKET: BY DOSAGE FORM, 2023-2030 (USD MILLION)

FIGURE 26 EUROPE NASAL SPRAY MARKET: BY DOSAGE FORM, CAGR (2023-2030)

FIGURE 27 EUROPE NASAL SPRAY MARKET: BY DOSAGE FORM, LIFELINE CURVE

FIGURE 28 EUROPE NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, 2022

FIGURE 29 EUROPE NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, 2023-2030 (USD MILLION)

FIGURE 30 EUROPE NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, CAGR (2023-2030)

FIGURE 31 EUROPE NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, LIFELINE CURVE

FIGURE 32 EUROPE NASAL SPRAY MARKET: BY APPLICATION, 2022

FIGURE 33 EUROPE NASAL SPRAY MARKET: BY APPLICATION, 2023-2030 (USD MILLION)

FIGURE 34 EUROPE NASAL SPRAY MARKET: BY APPLICATION, CAGR (2023-2030)

FIGURE 35 EUROPE NASAL SPRAY MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 36 EUROPE NASAL SPRAY MARKET: BY PRESCRIPTION/AVAILABILITY, 2022

FIGURE 37 EUROPE NASAL SPRAY MARKET: BY PRESCRIPTION/AVAILABILITY, 2023-2030 (USD MILLION)

FIGURE 38 EUROPE NASAL SPRAY MARKET: BY PRESCRIPTION/AVAILABILITY, CAGR (2023-2030)

FIGURE 39 EUROPE NASAL SPRAY MARKET: BY PRESCRIPTION/AVAILABILITY, LIFELINE CURVE

FIGURE 40 EUROPE NASAL SPRAY MARKET: BY END USER, 2022

FIGURE 41 EUROPE NASAL SPRAY MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 42 EUROPE NASAL SPRAY MARKET: BY END USER, CAGR (2023-2030)

FIGURE 43 EUROPE NASAL SPRAY MARKET: BY END USER, LIFELINE CURVE

FIGURE 44 EUROPE NASAL SPRAY MARKET: SNAPSHOT (2022)

FIGURE 45 EUROPE NASAL SPRAY MARKET: BY COUNTRY (2022)

FIGURE 46 EUROPE NASAL SPRAY MARKET: BY COUNTRY (2023 & 2030)

FIGURE 47 EUROPE NASAL SPRAY MARKET: BY COUNTRY (2022 & 2030)

FIGURE 48 EUROPE NASAL SPRAY MARKET: PRODUCT TYPE (2023-2030)

FIGURE 49 EUROPE NASAL SPRAY MARKET: COMPANY SHARE 2022 (%)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19